Merck & Co.
213 E Grand Ave, South San Francisco, CA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
33 Avenue Louis Pasteur, Boston, MA
320 Bent St, Cambridge, MA
NEWS
Roche announced that its Phase III IMpower 133 clinical trial of Tecentriq (atezolizumab) plus carboplatin and etoposide chemotherapy met its co-primary endpoints.
It’s a big week for the U.S. Food and Drug Administration (FDA) with plenty of upcoming decisions including Achaogen, GW Pharma, Merck and more.
Novo Nordisk’s semaglutide, an oral GLP-1 analogue, continues to rack up positive Phase III clinical trial data compared to its competitors.
June is Alzheimer’s & Brain Awareness Month and June 21 is dubbed “The Longest Day,” which focuses on raising awareness of Alzheimer’s disease.
Not only are women generally underrepresented in the biopharma industry, but compared to many of the top male executives, underpaid. Here’s a closer look at the top five female executives by pay in the biopharma industry.
Yet another drug for Alzheimer’s has been tossed in the trash. AstraZeneca and Eli Lilly announced they have abandoned two late-stage clinical trials of lanabecestat for Alzheimer’s disease.
The Bill and Melinda Gates Foundation has spun off a biotech company called The Bill & Melinda Gates Medical Research Institute (MRI) located in Boston. Although it found its temporary space in Cambridge, Massachusetts in January, it “officially” launched Thursday at the BIO International Convention in Boston.
BioMarin Pharmaceutical received $20 million in milestone payments from Pfizer after the U.S. Food and Drug Administration (FDA) and the European Medicines Agency (EMA) approved its applications for talazoparib.
One of the hot topics at this year’s BIO International Convention being held in Boston is “patient-centricity.”
JOBS
IN THE PRESS